Organoidsciences

OrganoidSciences was founded in 2018, originating from the organoid center of CHA Bundang Medical Center, and became the first company to list on KOSDAQ under Korea's newly created deep-tech special listing track in May 2025.

Its business is split into two pillars: the ATORM regenerative therapeutic platform, which engrafts organoids directly into damaged tissue to induce regeneration, and an organoid-based drug and material evaluation solutions business.

The therapeutic pipeline centers on the intestinal disease candidate ATORM-C, alongside ATORM-S for salivary gland hypofunction and additional liver and endometrium organoid candidates under development.

The evaluation solutions portfolio includes the spatial-biology gene analysis platform ODISEI, the researcher-facing culture service Organoize, the pharma-facing drug evaluation platform ADIO, and the material evaluation service organoEZ.

According to first-quarter 2026 revenue composition, domestic ODISEI sales accounted for more than half of revenue while organoEZ, combining domestic and export sales, made up roughly the other half, indicating some concentration in specific services.

Its joint-venture subsidiary PODO Therapeutics, formed with Severance Hospital, has commercialized ONCOSAYS, a body-fluid-based anticancer drug response prediction solution, while its German subsidiary Lambda Biologics is entering the European market with an antibody-drug conjugate evaluation platform.

Roughly twenty institutions, including Severance Hospital, use ODISEI, and the company signed a joint organoid-based drug development research agreement with JW Pharmaceutical in 2022.

The competitive landscape remains an early-stage market mixing domestic organoid startups such as MBD, QPeak Bio, and Cellbiotech with global organoid-on-chip companies, with the establishment of standardized regulatory validation frameworks flagged as a key variable for the industry's overall growth.

Consolidated 2025 revenue came to KRW 2.407 billion, up roughly 23% from KRW 1.953 billion in 2024, yet operating loss widened to KRW 16.20 billion from KRW 12.23 billion, and net loss attributable to owners grew to KRW 15.37 billion from KRW 11.25 billion.

The operating margin deteriorated further, from -626.4% in 2024 to -673.2% in 2025, reflecting rising R&D spending, listing-related costs, and overseas expansion investment that outpaced revenue growth.

Over the most recent four quarters (3Q25 through 2Q26), revenue swung sharply from KRW 320 million to KRW 1.227 billion, then to KRW 144 million and KRW 598 million, a pattern consistent with the project-based nature of evaluation solution contracts.

In contrast, operating loss expanded steadily each quarter, from KRW 3.907 billion to KRW 3.845 billion, KRW 4.243 billion, and KRW 4.354 billion, suggesting fixed-cost items have been rising regardless of revenue swings.

Notably, the 2Q26 net loss attributable to owners of KRW 6.725 billion significantly exceeded that quarter's operating loss of KRW 4.354 billion, indicating non-operating factors played a meaningful role in widening the bottom-line loss.

Full-year 2025 operating cash flow was negative KRW 13.99 billion, a faster cash-burn pace than the negative KRW 9.14 billion in 2024, contrasting with total equity that rose from KRW 15.29 billion to KRW 24.84 billion over the same period on listing and capital-raising proceeds.

The debt ratio declined from 69.3% in 2024 to 49.7% in 2025, a change driven more by equity expansion than by debt reduction.

The global organoid market is projected to grow at a compound annual rate of 21.9% to roughly $12.2 billion by 2030, as the US FDA and European EMA roll out roadmaps and draft guidelines to reduce reliance on animal testing, driving a shift in demand toward organoid and biomimetic-chip-based new approach methodologies (NAMs).

In October 2025, an anticancer drug candidate reportedly received FDA IND approval based solely on organoid data without animal testing, adding a concrete precedent to this industry transition.

In response, OrganoidSciences launched the K-NAMs platform together with more than 22 industry, academic, and research institutions to pursue test-method standardization, regulatory-compliance validation, and a foundation for commercialization.

At the same time, some observers note that Korea's domestic ecosystem, despite strong underlying technology, has lagged in establishing standardized validation frameworks and regulatory alignment, slowing real-world industrial adoption.

In terms of competitive positioning, OrganoidSciences holds a distinctive status as the sole Korean company whose organoid-based regenerative therapeutic technology was designated a national strategic technology by the Ministry of Trade, Industry and Energy in 2023, and it was also selected by the Animal Free Initiative as Korea's first certified NAMs testing institution.

The regenerative therapeutics segment remains an early-stage market globally where no company, domestic or international, has yet reached full commercialization, making the pace of clinical and regulatory data accumulation the key competitive variable.

The company obtained short-term efficacy data for Behcet's enteritis patients in an advanced regenerative medicine study of its intestinal therapeutic candidate ATORM-C, and it resubmitted a Phase 1 IND for the Crohn's disease indication at the end of December 2025, receiving MFDS approval roughly three months later according to company statements.

Following this, the company aims to begin a domestic Phase 1 trial and has set targets to file an FDA IND in 2026 and complete a global Phase 2 trial by 2028.

Its subsidiary PODO Therapeutics expects, per company commentary, that ONCOSAYS revenue from major domestic hospitals will ramp up in the second half of 2026, based on clinical data from more than one hundred patients.

In a December 16, 2025 report, Korea Investment & Securities projected that the mid- to long-term growth story would take shape as clinical progress in the regenerative therapeutics pipeline builds on ODISEI's stable revenue base, and it cited the company's own target of achieving KRW 10 billion in revenue and turning profitable by 2027; that report, however, did not issue an investment rating or a target price.

The company launched its K-NAMs platform at BIO KOREA 2026 held at COEX in April 2026 to expand the market for evaluation solutions such as ODISEI, and it is also pursuing expansion into Southeast Asian regenerative medicine markets including Thailand.

These targets remain contingent on clinical and regulatory procedures still in progress, and their actual achievement and timing will need to be confirmed through future disclosures.